Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15820063 | 0.89 | HCRTR2 (0.89) | HCRTR2HCRTR1 | |
| SCHEMBL16797398 | 0.88 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL15826046 | 0.87 | HCRTR2 (0.85) | HCRTR2HCRTR1 | |
| SCHEMBL15820392 | 0.85 | HCRTR2 (0.81) | HCRTR2HCRTR1 | |
| SCHEMBL15826053 | 0.83 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL16797405 | 0.82 | HCRTR1 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL19583479 | 0.82 | HCRTR1 (0.75) | HCRTR2HCRTR1 | |
| SCHEMBL17668256 | 0.80 | HCRTR2 (0.79) | HCRTR2HCRTR1 | |
| SCHEMBL16797840 | 0.80 | HCRTR2 (1.00) | HCRTR2HCRTR1 | |
| SCHEMBL15820007 | 0.80 | HCRTR2 (0.84) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934516-A1 | 3-ESTER-4-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | claimed |
| WO-2014099697-A1 | 3-ESTER-4-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | claimed |
| EP-3454857-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017194548-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-16 | — | — | WO | disclosed |
| EP-3223803-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-3218007-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016083315-A1 | USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016075134-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-05-19 | — | — | WO | disclosed |